Search results
Results From The WOW.Com Content Network
APS – TEVA UK Ltd; Assertio – Assertio Therapeutics, Inc; AstraZeneca – AstraZeneca UK Limited; Aventis Pharma – Sanofi-Aventis Ltd; Bausch & Lomb – Bausch & Lomb UK Ltd; Baxter – Baxter International; Baxter BioScience – Baxter International; Bayer – Bayer plc (Pharmaceutical Division) Becton Dickinson – Becton Dickinson UK Ltd
It was purchased from AstraZeneca by Bruntwood in 2014. The site has an international reputation as a home for bio and life sciences. The Alderley New Hall was constructed in brick with a stone facade for Baroness Maria and John, 7th Baronet (later 1st Baron) Stanley. Building started in 1818 on a site in the south of the park.
The UK is home to GlaxoSmithKline and AstraZeneca, respectively the world's fifth- and sixth-largest pharmaceutical companies measured by 2009 market share. [8] It is also home to the multinational Hikma Pharmaceuticals. Foreign companies with a major presence in the UK pharmaceutical industry include Pfizer, Novartis, [9] Hoffmann–La Roche ...
AstraZeneca (AZN.L) will keep its freeze on manufacturing investments in Britain if the country's exit from the European Union fails to give enough clarity on future trading relations, the ...
Drug Discovery company C4X Discovery Holdings plc has signed an exclusive worldwide licensing agreement with AstraZeneca plc (NASDAQ: AZN) worth up to $402 million for its NRF2 Activator program.
British finance minister Rachel Reeves wants to reduce state provisions to the company's vaccine centre, which will cut the pledge made by the previous administration from about 90 million pounds ...
AstraZeneca's primary listing is on the London Stock Exchange and is a constituent of the FTSE 100 Index; it also has a secondary listing on the Nasdaq Stockholm. It is also listed on the American Nasdaq and is a Nasdaq-100 company. AstraZeneca has one of the highest market capitalisations of pharmaceutical companies worldwide. [13]
(Reuters) -Britain's competition regulator is reviewing AstraZeneca's planned $39 billion takeover of U.S.-based Alexion on whether it could reduce competition in Britain or other markets. The UK ...